HC Wainwright Rates Hemab Therapeutics (COAG) buy

HC Wainwright maintains its buy rating on Hemab Therapeutics with a $40 price target, a 26.02% upside from the current price.

By EarningsIQ Research Desk · Published Jun 18, 2026, 3:02 AM EDT · Updated Jun 23, 2026, 10:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Hemab Therapeutics Holdings, Inc. ($COAG) "buy" with a $40 price target on June 17, 2026.

Since the rating, $COAG is up 8.7% after 1 week, up 86.3% after 1 month and up 13.7% to date (from the $26.45 close on Jun 17, 2026).

COAG Hemab Therapeutics Holdings, Inc.

$30.07 -32.47% past 3 months

Daily close · Oct 16, 2026

Key Points

HC Wainwright reiterated a buy rating on Hemab Therapeutics, setting a $40 price target on June 17, 2026.
HC Wainwright's $40 price target implies 26.02% upside from Hemab Therapeutics Holdings, Inc.'s ($COAG) current $31.74 share price.
Hemab Therapeutics shares are trading around $25.51, with a market cap of approximately $1.17 billion and a forward P/E of -11.38.
Analysts have a strong buy consensus on Hemab, with a mean price target of $41.75 among four opinions.

Get $COAG trade alerts by text

We text you when insiders, Congress or big funds trade $COAG. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Hemab Therapeutics Holdings, Inc. alert may contain errors. Disclosures

On June 17, 2026, HC Wainwright reiterated its buy rating for Hemab Therapeutics Holdings, Inc. (NasdaqGS:COAG) and set a price target of $40. Analyst Emily Bodnar's reaffirmation suggests confidence in the company's potential.

Analysts Set New Price Targets

On June 17, 2026, HC Wainwright & Co. reiterated its buy rating on Hemab Therapeutics with a $40 price target. This aligns with other recent analyst activities, with Wedbush, Jefferies, Evercore ISI Group, and Goldman Sachs all initiating coverage with buy ratings and price targets ranging from $36 to $50 in late May 2026. The consensus among analysts is a strong buy, with a mean target price of $41.75 from four analyst opinions.

Hemab Therapeutics Holdings, Inc. Stock Down 22.9%

Shares of Hemab Therapeutics (NasdaqGS:COAG) are currently trading around $25.51. The company has a market capitalization of about $1.17 billion. Despite not being profitable, its forward price-to-earnings ratio stands at -11.38. The stock's 52-week price range is between $23.00 and $36.61, with both the 50-day and 200-day moving averages at approximately $26.63. Hemab maintains a strong liquidity position, with a current ratio of 18.03 and a quick ratio of 17.62.

12-month forecast

$COAG price target

Hemab Therapeutics Holdings, Inc. daily closes and this analyst's $40 target. Not advice.

About Hemab Therapeutics

Hemab Therapeutics Holdings, Inc. is a biotechnology company focused on developing innovative therapies for blood coagulation disorders. Based in Cambridge, Massachusetts, and founded in 2020, the company is led by CEO Dr. Benny Sorensen. Hemab's pipeline includes HMB-001, a bispecific antibody in Phase 1/2 trials for Glanzmann thrombasthenia and Factor VII deficiency, and HMB-002, a monovalent antibody for Von Willebrand disease. The company operates in the U.S. and Denmark, advancing several preclinical and discovery-stage assets.

Bottom Line

HC Wainwright's reiterated buy rating and $40 price target for Hemab Therapeutics highlight ongoing confidence in the company's prospects. With shares trading at $25.51 and a market cap of $1.17 billion, the stock remains a focus for investors tracking the biotechnology sector. As a reminder, analyst ratings and targets reflect professional opinions and are subject to change based on future developments.